RecruitingPhase 4NCT05967117

Chest CT Using Low-concentration Iodine Contrast Media

Chest CT Using Low-concentration Iodine Contrast Media - a Prospective Multicenter Comparative Study


Sponsor

Jung Im Jung

Enrollment

370 participants

Start Date

Nov 24, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to evaluate the quality of images when low-concentration iodine contrast agents is used in chest CT with low tube voltage and if they can be used in routine imaging. The primary endpoint of the study was the quality of the image and comparison of chest CT by using low and conventional concentration iodine contrast agents with low tube voltage and chest CT by using the conventional concentration iodine contrast agents with the conventional tube voltage; The secondary endpoint is optimizing chest CT protocol using an iodine contrast agent.


Eligibility

Min Age: 19 Years

Inclusion Criteria1

  • Patients aged 19 years or older, weighing less than 90 kg, and BMI less than 30 who underwent contrast-enhanced chest CT alone

Exclusion Criteria9

  • Under the age of 18
  • Cases where contrast-enhanced CT cannot be performed
  • Heart failure
  • Pregnancy
  • If patients cannot voluntarily give written consent to participate in this clinical trial
  • In the case of an anatomical deformation that may interfere with image analysis in the previous image
  • Patients with a history of hypersensitivity to IOBRIX, components of IOBRIX, and iodine-based drugs
  • Patients with severe thyroid disease (Iodine may accumulate in the thyroid gland and worsen symptoms.)
  • Those who are judged unsuitable by the tester for other reasons Patients aged 19 years or older, weighing less than 90 kg, and BMI less than 30 who underwent contrast-enhanced chest CT alone

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIohexol (320mgI/mL) with 120kVp

Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

DRUGIohexol (320mgI/mL) with 100kVp

Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

DRUGIohexol (270mgI/mL) with 100kVp

Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

DRUGIohexol (240mgI/mL) with 100kVp

Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.


Locations(6)

Bucheon St. Mary's Hospital, The Catholic University of Korea

Bucheon-si, Gyeonggi-do, South Korea

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, South Korea

Jeonbuk National University Hospital

Jeonju, Jeollabuk-do, South Korea

Seoul St. Mary's Hospital, The Catholic University of Korea

Seoul, Seocho-gu, South Korea

Chonnam National University Hospital

Gwangju, South Korea

Seoul National University Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05967117


Related Trials